Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Clinical and Correlative Phase II Study

Trial Profile

Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Clinical and Correlative Phase II Study

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Dec 2022 Results assessing the molecular variants associated with resistance to a quadruplet treatment combination in newly diagnosed multiple myeloma treated with targeted-immunotherapy, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
    • 14 Dec 2021 Plasma cells from bone marrow (BM) samples from patients from this and another study (NCT03290950) were used to predict genomic and immune signatures, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
    • 10 Feb 2021 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top